On The Fly
|
Check out this evening's… ShowHide Related Items >><< - 11/17/22
- Williams-Sonoma falls 11% to $116.15 after Q3 results
- 11/17/22
- Williams-Sonoma backs FY22 guidance of mid-to-high single digit revenue growth
- 09/14/22
- Williams-Sonoma names Jeff Howie as new CFO
- 09/13/22
- West Elm, office furniture startup Branch announce retail partnership
- 11/03/22
- StoneCo announces Pedro Zinner to succeed Thiago Piau as CEO
- 06/02/22
- StoneCo jumps 24% to $12.95 after Q1 results
- 06/01/22
- StoneCo to submit reduction in voting power concentration to BCB
- 11/17/22
- Ross Stores jumps 15% to $112.50 after Q3 results beat, FY22 EPS view raised
- 11/14/22
- Soros Fund Management buys Sierra Wireless, exits Kinder Morgan in Q3
- 10/16/22
- Fly Intel: Top five weekend stock stories
- 07/14/22
- Ross Stores extends employment contract of CMO Morrow through March 2026
- 11/17/22
- Rapt Therapeutics falls 7% to $19.70 after $75M common stock offering
- 09/28/22
- Rapt appoints Jennifer Nicholson as SVP, regulatory affairs, quality assurance
- 05/25/22
- Rapt Therapeutics announces private placement financing of $50M
- 05/23/22
- Rapt Therapeutics announces initiation of Phase 2b trial of RPT193
- 11/17/22
- Palo Alto Networks CEO: We're taking a knife to our costs
- 11/17/22
- Palo Alto Networks jumps 5% after Q1 results, FY23 guidance beat estimates
- 11/17/22
- Palo Alto Networks confirms agreement to acquire Cider Security for $195M cash
- 11/17/22
- Palo Alto Networks announces receipt of initial $67M purchase order from DOD
- 11/17/22
- Matthews sees FY23 adjusted EBITDA $215M-$235M
- 11/16/22
- Matthews boosts dividend to 23c per share
- 08/17/22
- Matthews acquires OLBRICH, R+S Automotive for EUR 43M
- 06/21/22
- Matthews to acquire Olbrich and R+S Automotive for $45M
KEYS Keysight Technologies - $166.06 /
-0.575 (-0.35%) - 11/09/22
- Nokia Bell Labs selects Keysight's sub-THz test bed to verify TRX modules
- 10/04/22
- Keysight Technologies SVP Page sells 6,910
- 09/21/22
- Keysight Technologies, Jiyun Technologies collaborate on battery test system
- 09/08/22
- Keysight Technologies signs MOU with IBM for RAN deployments in Europe
- 11/17/22
- Iveric bio announces FDA granted breakthrough designation for Zimura
- 11/03/22
- Iveric bio submits first part of NDA for rolling review of avacincaptad pegol
- 09/06/22
- Iveric bio says GATHER2 Phase 3 trial met primary endpoint
- 09/02/22
- Iveric bio reports inducement grants under Nasdaq Listing Rule
- 11/02/22
- G1 Therapeutics reports data from first patients in Phase 2 study of trilaciclib
- 10/26/22
- G1 announces investigator-initiated study of trilaciclib, lurbinectedin
- 10/10/22
- G1 Therapeutics completes enrollment in Phase 3 clinical trial of trilaciclib
- 09/12/22
- Day One Biopharmaceuticals appoints Nicholson as chairman
- 11/17/22
- Gap rises 8% to nearly $14 after Q3 results
- 11/10/22
- Gap launches collection of 'family essentials' with Amazon Fashion
- 10/25/22
- Gap 'taking immediate steps' to remove Yeezy Gap product from stores
- 09/28/22
- Gap unit Athleta teams with thredUP, and Shop Premium Outlets for online
- 08/30/22
- Gambling.com ready for online sports betting launch in Kansas
- 07/06/22
- Gambling com Group Ltd trading resumes
- 07/06/22
- Gambling com Group Ltd trading halted, volatility trading pause
- 06/08/22
- Gambling.com set to join Russell 3000 Index
- 10/21/22
- Farfetch announces first cohort of start-ups for Dream Assembly Base Camp
- 08/29/22
- Farfetch falls -11.9%
- 08/26/22
- Farfetch rises 27.3%
- 08/26/22
- Farfetch rises 24.4%
- 11/17/22
- Centene signs agreement to sell Magellan Specialty Health to Evolent Health
- 11/17/22
- Evolent Health to acquire NIA for $650M upfront consideration
- 10/12/22
- Evolent Health sees revenue related to Bright Health as flat from 2022 to 2023
- 06/29/22
- Evolent Health to acquire IPG from TPG for $375M in cash
- 11/16/22
- Wafer Fab Equipment names slide after Micron cuts wafer starts
- 10/24/22
- Applied Materials appoints March to board of directors
- 10/19/22
- Microvast, Albemarle among infrastructure law funding recipients
- 09/11/22
- Fly Intel: Top five weekend stock stories
- 10/25/22 Morgan Stanley
- Ross Stores price target raised to $119 from $118 at Morgan Stanley
- 10/25/22 Wells Fargo
- Ross Stores upgraded to Overweight from Equal Weight at Wells Fargo
- 09/16/22 JPMorgan
- Ross Stores price target raised to $112 from $98 at JPMorgan
- 08/22/22 Barclays
- Ross Stores price target raised to $98 from $85 at Barclays
- 09/06/22 Goldman Sachs
- StoneCo downgraded to Sell from Neutral at Goldman Sachs
- 08/23/22 Susquehanna
- StoneCo results strong on TPV growth, says Susquehanna
- 07/11/22 Susquehanna
- StoneCo price target lowered to $20 from $28 at Susquehanna
- 04/08/22 Cantor Fitzgerald
- StoneCo initiated with an Overweight at Cantor Fitzgerald
- 10/25/22 Truist
- Gambling.com price target raised to $12 from $10.50 at Truist
- 08/30/22 Truist
- Gambling.com price target lowered to $10.50 from $12 at Truist
- 01/13/22 Truist
- Gambling.com price target lowered to $13 from $17 at Truist
- 11/11/22 Citi
- Gap price target raised to $8 from $7 at Citi
- 09/16/22 JPMorgan
- Gap price target raised to $9 from $8 at JPMorgan
- 08/31/22 Cowen
- Gap price target lowered to $10 from $12 at Cowen
- 08/30/22 Barclays
- Barclays ups Gap to Equal Weight, says risks now known
- 11/16/22 KeyBanc
- Palo Alto Networks price target lowered to $210 from $227 at KeyBanc
- 11/15/22 MKM Partners
- Palo Alto Networks price target lowered to $220 from $250 at MKM Partners
- 11/14/22 Barclays
- Palo Alto Networks price target lowered to $200 from $232 at Barclays
- 11/10/22 Loop Capital
- Palo Alto Networks upgraded to Buy at Loop Capital on accelerating enterprise
- 07/20/22 B. Riley
- Matthews price target lowered to $45 from $50 at B. Riley
- 11/17/22 Citi
- Applied Materials price target lowered to $135 from $150 at Citi
- 10/28/22 Cowen
- Applied Materials price target lowered to $279 from $347 at Cowen
- 10/21/22 New Street
- Applied Materials, ASML upgraded at New Street ahead of earnings trough
- 10/21/22 New Street
- Applied Materials upgraded to Buy from Neutral at New Street
KEYS Keysight Technologies - $166.06 /
-0.575 (-0.35%) - 11/03/22 Wells Fargo
- Keysight Technologies initiated with an Overweight at Wells Fargo
- 10/10/22 JPMorgan
- Keysight Technologies price target raised to $225 from $215 at JPMorgan
- 08/19/22 BofA
- Keysight Technologies price target raised to $185 from $155 at BofA
- 08/18/22 Deutsche Bank
- Keysight Technologies price target raised to $193 from $190 at Deutsche Bank
- 11/10/22 Jefferies
- Apellis downgraded to Hold at Jefferies after doctor survey
- 11/10/22 Jefferies
- Iveric bio downgraded to Hold at Jefferies after doctor survey
- 11/10/22 Jefferies
- Iveric bio downgraded to Hold from Buy at Jefferies
- 10/17/22 B. Riley
- Iveric bio upgraded to Neutral at B. Riley after competitor in GA 'disappoints'
- 11/04/22 Piper Sandler
- Evolent should be bought on 'unfounded sell-off,' says Piper Sandler
- 11/03/22 Canaccord
- Evolent Health price target lowered to $44 from $48 at Canaccord
- 11/01/22 Truist
- Evolent Health initiated with a Hold at Truist
- 10/12/22 Canaccord
- Evolent Health price target lowered to $48 from $55 at Canaccord
- 10/25/22 Morgan Stanley
- Farfetch price target lowered to $26 from $32 at Morgan Stanley
- 10/12/22 Wells Fargo
- Wells names Farfetch 'Top Pick' after Platform Solutions deep dive
- 10/11/22 Morgan Stanley
- Farfetch recent deals 'underappreciated and mis-priced,' says Morgan Stanley
- 09/26/22 Citi
- Farfetch initiated with a Sell at Citi
- 11/11/22 JPMorgan
- Williams-Sonoma price target lowered to $131 from $143 at JPMorgan
- 11/08/22 Wedbush
- Wedbush downgrades Williams-Sonoma to Neutral, lowers price target to $110
- 11/08/22 Wedbush
- Williams-Sonoma downgraded to Neutral from Outperform at Wedbush
- 10/31/22 Citi
- Williams-Sonoma price target lowered to $135 from $156 at Citi
- 10/14/22 Tigress Financial
- Dolby price target lowered to $116 from $128 at Tigress Financial
- 06/08/22
- Baird to hold a conference
- 05/23/22 Rosenblatt
- Dolby initiated with a Buy at Rosenblatt
- 11/02/22 H.C. Wainwright
- G1 Therapeutics price target lowered to $57 from $67 at H.C. Wainwright
- 09/16/22 Wedbush
- G1 Therapeutics price target raised to $25 from $20 at Wedbush
- 11/14/22 H.C. Wainwright
- Rapt Therapeutics price target lowered to $50 from $53 at H.C. Wainwright
- 11/10/22 Piper Sandler
- Rapt Therapeutics price target raised to $34 from $30 at Piper Sandler
- 09/21/22 Capital One
- Capital One starts Rapt with Overweight, sees 100% upside
- 09/21/22 Capital One
- Rapt Therapeutics initiated with an Overweight at Capital One
- 11/17/22
- Williams-Sonoma reports Q3 EPS $3.72, consensus $3.71
- 08/24/22
- Williams-Sonoma backs FY22 and long term guidance
- 08/24/22
- Williams-Sonoma reports Q2 EPS $3.87, consensus $3.54
- 11/17/22
- StoneCo reports Q3 adjusted EPS R$0.52 vs. R$0.30 last year
- 08/18/22
- StoneCo sees Q3 revenue above R$ 2.4B, up 63 y/y
- 08/18/22
- StoneCo reports Q2 EBT R$ 107M, up 29.4 from Q1
- 06/02/22
- StoneCo reports Q1 adjusted EPS R$0.43 vs. R$0.60 last year
- 11/17/22
- Ross Stores raises FY22 EPS view to $4.21-$4.34 from $3.84-$4.12
- 11/17/22
- Ross Stores sees Q4 EPS $1.13-$1.26, consensus $1.13
- 11/17/22
- Ross Stores reports Q3 EPS $1.00, consensus 81c
- 11/17/22
- Notable companies reporting after market close
- 11/10/22
- Rapt Therapeutics reports Q3 EPS (63c), consensus (67c)
- 08/11/22
- Rapt Therapeutics reports Q2 EPS (62c), consensus (75c)
- 11/17/22
- Palo Alto Networks sees FY23 adjusted EPS $3.37-$3.44, consensus $3.17
- 11/17/22
- Palo Alto Networks sees Q2 adjusted EPS 76c-78c, consensus 71c
- 11/17/22
- Palo Alto Networks reports Q1 adjusted EPS 83c, consensus 69c
- 11/17/22
- Matthews reports Q4 EPS 82c, consensus 72c
- 07/28/22
- Matthews on track to deliver consolidated sales growth for FY22
- 07/28/22
- Matthews reports Q3 EPS 58c, consensus 62c
KEYS Keysight Technologies - $166.06 /
-0.575 (-0.35%) - 11/17/22
- Keysight Technologies sees Q1 adjusted EPS $1.81-$1.87, consensus $1.81
- 11/17/22
- Keysight Technologies reports Q4 adjusted EPS $2.14, consensus $1.99
- 08/17/22
- Keysight Technologies sees Q4 adjusted EPS $1.94-$2.00, consensus $1.89
- 08/17/22
- Keysight Technologies reports Q3 adjusted EPS $2.01, consensus $1.78
- 11/03/22
- Iveric bio reports Q3 EPS (35c), consensus (40c)
- 07/26/22
- Iveric bio reports Q2 EPS (42c), consensus (31c)
- 11/02/22
- G1 Therapeutics reports Q3 EPS (59c), consensus (63c)
- 08/03/22
- G1 Therapeutics reports Q2 EPS (92c), consensus ($1.02)
- 11/17/22
- Gap reports Q3 Gap brand revenue $1.04B, flat y/y
- 11/17/22
- Gap sees Q4 revenue down mid-single digits, consensus $4.5B
- 11/17/22
- Gap reports Q3 adjusted EPS 71c, consensus 0c
- 11/17/22
- Gambling.com backs FY22 revenue $71M-$76M, consensus $71M
- 11/17/22
- Gambling.com reports Q3 adjusted EPS 16c, two estimates 5c
- 08/29/22
- Gambling.com backs FY22 revenue view $71M-$76M, consensus $71.08M
- 08/29/22
- Gambling.com reports Q2 adjusted EPS 9c vs 8c last year
- 11/17/22
- Farfetch reports Q3 adjusted EPS (24c), consensus (28c)
- 08/25/22
- Farfetch reports Q2 EPS (21c), consensus (32c)
- 05/26/22
- Farfetch reports Q1 EPS (24c), consensus (28c)
- 11/17/22
- Evolent Health expects FY23 revenue growth to exceed 25%, consensus $1.64B
- 11/02/22
- Evolent Health sees FY22 revenue $1.33B-$1.35, consensus $1.35B
- 11/02/22
- Evolent Health sees Q4 revenue $361M-$381M, consensus $376.16M
- 11/02/22
- Evolent Health reports Q3 adjusted EPS 62c, consensus 12c
- 11/17/22
- Dolby says FY23 revenue expected to grow low single digits year-over-year
- 11/17/22
- Dolby sees Q1 EPS 76c-91c, consensus $1.10
- 11/17/22
- Dolby reports Q4 EPS 54c, consensus 60c
- 08/09/22
- Dolby sees FY22 EPS $3.22-$3.37, consensus $3.39
- 11/17/22
- Delta Apparel reports Q4 EPS (4c) vs. 96c last year
- 11/17/22
- Applied Materials sees Q1 adjusted EPS $1.75-$2.11, consensus $1.83
- 11/17/22
- Applied Materials reports Q4 adjusted EPS $2.03, consensus $1.73
- 10/12/22
- Applied Materials cuts Q4 adjusted EPS view to $1.54-$1.78 from $1.82-$2.18
|
Hot Stocks
|
Bartolacci further… Bartolacci further stated: "As we look forward into fiscal 2023, we are currently projecting another year of consolidated sales growth. Order rates for our Industrial Technologies segment, particularly energy storage solutions, support our confidence in the continued growth of this segment next fiscal year. We also expect the recent acquisitions of Olbrich GmbH and R+S Automotive GmbH to significantly contribute to the segment's fiscal 2023 sales. Based on these expectations and considering the increasing interest across our entire energy storage solutions portfolio, it's possible annual sales for the Industrial Technologies segment could approach $500 million in fiscal 2023. For our Memorialization segment, we expect death rates to continue to normalize into fiscal 2023. We also expect the comparability challenges on unit volumes (primarily through the first three quarters of fiscal 2023) to be partially mitigated by recent pricing actions as well as growth in our cremation-related sales. Further, despite the ongoing challenges in our European markets, we are currently projecting improved performance for our SGK Brand Solutions segment resulting from their recent cost reduction initiatives. However, we expect currency rates to continue to impact year-over-year comparability. Accordingly, based on these considerations, we currently project consolidated adjusted EBITDA to be in the range of $215 million to $235 million for fiscal 2023. We remain cautious in our outlook as our results will be influenced by the timing of projects and current economic conditions, particularly in Europe and its impact on currency rates." ShowHide Related Items >><< - 11/16/22
- Matthews boosts dividend to 23c per share
- 08/17/22
- Matthews acquires OLBRICH, R+S Automotive for EUR 43M
- 06/21/22
- Matthews to acquire Olbrich and R+S Automotive for $45M
- 07/20/22 B. Riley
- Matthews price target lowered to $45 from $50 at B. Riley
- 11/17/22
- Matthews reports Q4 EPS 82c, consensus 72c
- 07/28/22
- Matthews on track to deliver consolidated sales growth for FY22
- 07/28/22
- Matthews reports Q3 EPS 58c, consensus 62c
|